Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has The Biosimilar Hormones Market Size Shifted, And What Is the Outlook Through 2034?

The market size for biosimilar hormones has seen a significant increase recently. Its growth trajectory indicates a rise from $3.9 billion in 2024 to $4.98 billion in 2025 at a compound annual growth rate (CAGR) of 27.5%. Factors contributing to this upward trend during the historic period include the growing occurrence of chronic illnesses, the increasing elderly population, enhanced understanding of biosimilar hormones, and broader access to healthcare services.

How Much Will the Biosimilar Hormones Market Be Worth in 2029?

The market size of biosimilar hormones is predicted to experience significant expansion in the coming years, potentially reaching a value of $11.77 billion in 2029 with a compound annual growth rate (CAGR) of 24.0%. Factors contributing to this anticipated growth during the forecast period are an increase in hormone targets, patient acceptance, advancements in manufacturing processes, government backing, expanding clinical trial data, and wider access to healthcare facilities. Key trends predicted for the forecast period include the adoption of personalized hormone replacement, the introduction of new products, issues related to pricing and access, and a focus on patient-oriented care.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3432&type=smp

Which is the Largest Company in the Biosimilar Hormones Market?

Major companies operating in the biosimilar hormones market include Teva Pharmaceutical Industries Ltd., Gedeon Richter Plc., Intas Pharmaceuticals Ltd., Biocon Limited, Mylan, Sanofi, Sandoz Group AG, LG Life Sciences, Ferring Pharmaceuticals, GC Pharma, Pfizer Inc., Dr. Reddy’s Laboratories, Amgen Inc., Eli Lilly and Company, Celltrion Inc., Samsungbioepis Co.Ltd, Merck & Co., Biogen Inc., Boehringer Ingelheim, Alvotech, BioXpress Therapeutics, Cipla Limited, Lupin Ltd., Stada Arzneimittel AG, Torrent Pharmaceuticals, Zydus Cadila, Accord Healthcare, Hetero Drugs, Wockhardt

What Are the Main Market Drivers in the Biosimilar Hormones Industry?

The biosimilar hormones market has grown due to the increasing need to address hormonal deficiencies, particularly in growth and metabolic hormones. Hormone therapies have advanced significantly throughout the years, which has only fueled a higher demand for products in this market sector. The British Medical Journal, a peer-reviewed medical journal based in the UK, reported in January 2022 that it is estimated that anywhere from 1 in 3,500 to 1 in 10,000 children globally suffer from GH deficiency (GHD). A Medscape report from June 2022 also highlighted the expectation that roughly 6,000 adults in the USA are likely to be diagnosed with a deficiency in growth hormones (GH). The steady occurrence of hormonal deficiencies and the subsequent need for treatment is a significant factor propelling the growth of the biosimilar hormones market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=3432&type=smp

How Is the Biosimilar Hormones Market Segments Structured?

The biosimilar hormones market covered in this report is segmented –

1) By Type: Teriparatide Biosimilars, Follitropin Alfa Biosimilars, Insulin Biosimilars, Somatropin Biosimilars, Other Types

2) By Application: Research & Biotechnology, Diagnostics, Biocatalysts, Therapeutics, Other Applications

3) By Distribution Channel: Hospital And Retail Pharmacy, Online Pharmacy/pharmacy, Specialty Clinics

Subsegments:

1) By Teriparatide Biosimilars: Osteoporosis Treatment, Bone Health Maintenance

2) By Follitropin Alfa Biosimilars: Infertility Treatment, Assisted Reproductive Technology (ART)

3) By Insulin Biosimilars: Type 1 Diabetes Management, Type 2 Diabetes Management

4) By Somatropin Biosimilars: Growth Hormone Deficiency Treatment, Pediatric Growth Disorders

5) By Other Types: Thyroid Hormones, Corticosteroids

What Strategic Trends Are Transforming the Biosimilar Hormones Market?

Major figures in the biosimilar hormones market are employing several strategic approaches, including releasing new products in under-served regions, to broaden the reach of their drug to a larger demographic. They’re concentrating on diversifying the locations for their product launches to inflate sales and escalate profits. For example, Alvotech Holdings S.A., a Luxembourg-based biopharmaceutical enterprise with a focus on biosimilar medicine development, confirmed a collaboration with Fuji Pharma Co. Ltd., a pharmaceutical business from Japan, for the advancement of biosimilar drug contenders in Japan in February 2022. They have both pledged to enrich their strategic partnership with new components to facilitate the birth and promotion of biosimilar medication in Japan.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report

Which Global Regions Offer the Highest Growth in the Biosimilar Hormones Market?

The countries covered in the biosimilar hormones market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3432

This Report Delivers Insight On:

1. How big is the biosimilar hormones market, and how is it changing globally?

2. Who are the major companies in the biosimilar hormones market, and how are they performing?

3. What are the key opportunities and risks in the biosimilar hormones market right now?

4. Which products or customer segments are growing the most in the biosimilar hormones market?

5. What factors are helping or slowing down the growth of the biosimilar hormones market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model